Mark L. Hartman

10.1k total citations · 5 hit papers
103 papers, 7.3k citations indexed

About

Mark L. Hartman is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Epidemiology. According to data from OpenAlex, Mark L. Hartman has authored 103 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Endocrinology, Diabetes and Metabolism, 31 papers in Physiology and 19 papers in Epidemiology. Recurrent topics in Mark L. Hartman's work include Growth Hormone and Insulin-like Growth Factors (48 papers), Pituitary Gland Disorders and Treatments (18 papers) and Diet and metabolism studies (17 papers). Mark L. Hartman is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (48 papers), Pituitary Gland Disorders and Treatments (18 papers) and Diet and metabolism studies (17 papers). Mark L. Hartman collaborates with scholars based in United States, Netherlands and United Kingdom. Mark L. Hartman's co-authors include Michael O. Thorner, Johannes D. Veldhuis, Arthur Weltman, Judy Y. Weltman, Axel Haupt, Suzan S. Pezzoli, Michael L. Johnson, Jill A. Kanaley, Jody L. Clasey and Yu Du and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Mark L. Hartman

98 papers receiving 7.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 549 citations Axel Haupt, Zvonko Miličević et al. New England Journal of Medicine profile →
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

2024 353 citations Rohit Loomba, Mark L. Hartman et al. New England Journal of Medicine profile →
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

2020 271 citations Mark L. Hartman, Arun J. Sanyal et al. Diabetes Care profile →
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

2023 232 citations Julio Rosenstock, Melissa K. Thomas et al. profile →
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

2024 118 citations Arun J. Sanyal, Bram Brouwers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark L. Hartman United States	46	4.8k	2.4k	1.3k	1.0k	1.0k	103	7.3k
Andrea Fabbri Italy	48	3.8k 0.8×	1.4k 0.6×	836 0.7×	1.4k 1.4×	676 0.7×	155	7.8k
Fausto Santeusanio Italy	52	4.7k 1.0×	1.6k 0.6×	562 0.4×	1.3k 1.2×	723 0.7×	176	7.9k
Erik Endert Netherlands	47	2.4k 0.5×	2.5k 1.0×	884 0.7×	1.0k 1.0×	958 0.9×	186	8.1k
Jonathan Krakoff United States	48	1.8k 0.4×	3.6k 1.5×	1.3k 1.0×	1.7k 1.6×	2.0k 2.0×	206	8.2k
Renato Pasquali Italy	61	5.4k 1.1×	2.5k 1.0×	1.6k 1.3×	1.5k 1.4×	1.1k 1.1×	190	15.2k
Pierpaolo De Feo Italy	43	2.8k 0.6×	1.8k 0.7×	637 0.5×	585 0.6×	497 0.5×	123	5.4k
Martin Bidlingmaier Germany	56	7.0k 1.5×	2.1k 0.9×	2.0k 1.6×	1.9k 1.8×	951 0.9×	373	11.4k
Hershel Raff United States	45	4.7k 1.0×	1.2k 0.5×	728 0.6×	755 0.7×	360 0.4×	247	8.5k
Andrea Caumo Italy	41	2.3k 0.5×	1.4k 0.6×	578 0.5×	1.3k 1.2×	553 0.5×	139	5.2k
B Guy-Grand France	42	1.2k 0.3×	3.1k 1.3×	2.5k 2.0×	853 0.8×	1.3k 1.3×	137	7.1k

Countries citing papers authored by Mark L. Hartman

Since Specialization

Citations

This map shows the geographic impact of Mark L. Hartman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Hartman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Hartman more than expected).

Fields of papers citing papers by Mark L. Hartman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Hartman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Hartman. The network helps show where Mark L. Hartman may publish in the future.

Co-authorship network of co-authors of Mark L. Hartman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Hartman. A scholar is included among the top collaborators of Mark L. Hartman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Hartman. Mark L. Hartman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hartman, Mark L., Rohit Loomba, Eric Lawitz, et al.. (2025). Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide. JHEP Reports. 7(8). 101472–101472. 1 indexed citations

Wen, Yi, Yanzhu Lin, Yan Chen, et al.. (2025). Decreases in circulating ANGPTL3 /8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obesity and Metabolism. 27(10). 5985–5995. 1 indexed citations

Caussy, Cyrielle, Kenneth Cusi, Julio Rosenstock, et al.. (2025). Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. Diabetes Care. 48(12). 2074–2083.

Brouwers, Bram, Girish S. Rao, Yuanyuan Tang, et al.. (2024). Incretin-based investigational therapies for the treatment of MASLD/MASH. Diabetes Research and Clinical Practice. 211. 111675–111675. 18 indexed citations

Loomba, Rohit, Mark L. Hartman, Eric Lawitz, et al.. (2024). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 391(4). 299–310. 353 indexed citations breakdown →

Moore, Dale A., Jared Taylor, Mark L. Hartman, & William M. Sischo. (2009). Quality assessments of waste milk at a calf ranch. Journal of Dairy Science. 92(7). 3503–3509. 65 indexed citations

Weltman, Arthur, Jean Després, Jody L. Clasey, et al.. (2003). Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults. Metabolism. 52(1). 73–80. 40 indexed citations

Hartman, Mark L., Brenda Crowe, Beverly M. K. Biller, et al.. (2002). Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency?. The Journal of Clinical Endocrinology & Metabolism. 87(2). 477–485. 239 indexed citations

Wideman, Laurie, Judy Y. Weltman, Mark L. Hartman, Johannes D. Veldhuis, & Arthur Weltman. (2002). Growth Hormone Release During Acute and Chronic Aerobic and Resistance Exercise. Sports Medicine. 32(15). 987–1004. 137 indexed citations

10.

Kanaley, Jill A., Judy Y. Weltman, Karen S. Pieper, Arthur Weltman, & Mark L. Hartman. (2001). Cortisol and Growth Hormone Responses to Exercise at Different Times of Day¹. The Journal of Clinical Endocrinology & Metabolism. 86(6). 2881–2889. 159 indexed citations

11.

Hartman, Mark L., et al.. (2000). Predictors of Growth Hormone Secretion in Aging. 3(3). 303–314. 2 indexed citations

12.

Clasey, Jody L., Claude Bouchard, Charles D. Teates, et al.. (1999). The Use of Anthropometric and Dual‐Energy X‐ray Absorptiometry (DXA) Measures to Estimate Total Abdominal and Abdominal Visceral Fat in Men and Women. Obesity Research. 7(3). 256–264. 186 indexed citations

13.

Weltman, Arthur, Judy Y. Weltman, Jill A. Kanaley, et al.. (1998). Repeated bouts of exercise alter the blood lactate-RPE relation. Medicine & Science in Sports & Exercise. 30(7). 1113–1117. 20 indexed citations

14.

Kirk, Susan E., Barry J. Gertz, Stephen H. Schneider, et al.. (1997). Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men¹. The Journal of Clinical Endocrinology & Metabolism. 82(4). 1154–1159. 17 indexed citations

15.

Weltman, Arthur, Judy Y. Weltman, Christopher J. Womack, et al.. (1997). Exercise training decreases the growth hormone (GH) response to acute constant-load exercise. Medicine & Science in Sports & Exercise. 29(5). 669–676. 45 indexed citations

16.

Hartman, Mark L., Johannes D. Veldhuis, & Michael O. Thorner. (1993). Normal Control of Growth Hormone Secretion. Hormone Research. 40(1-3). 37–47. 117 indexed citations

17.

Hartman, Mark L., Peter Clayton, Michael L. Johnson, et al.. (1993). A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.. Journal of Clinical Investigation. 91(6). 2453–2462. 154 indexed citations

18.

Hartman, Mark L., et al.. (1993). Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.. The Journal of Clinical Endocrinology & Metabolism. 76(5). 1202–1208. 80 indexed citations

19.

Vance, Mary Lee, Mark L. Hartman, & Michael O. Thorner. (1992). Growth Hormone and Nutrition. Hormone Research. 38(1). 85–88. 62 indexed citations

20.

Hartman, Mark L., et al.. (1990). Somatotropin Pulse Frequency and Basal Concentrations Are Increased in Acromegaly and Are Reduced by Successful Therapy*. The Journal of Clinical Endocrinology & Metabolism. 70(5). 1375–1384. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact